FOLD News and Press, Amicus Therapeutics Inc. From 10/02/23

Refinancing of Current $400M Debt at Lower Cost and Improved Amortization Schedule Blackstone to also Purchase $30M of Amicus Common Stock PRINCETON, N.J., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a global, patient-dedicated biotechnology company focus...

2023-09-29 11:00:14 ET Summary Shares of Amicus Therapeutics declined after FDA approval of Pombiliti and Opfolda for late-onset Pompe disease due to a worse-than-expected label. The label states that only patients not improving on existing treatments are eligible for Pombiliti an...

2023-09-28 11:27:36 ET More on Amicus Therapeutics Amicus closes up 5% as it expects approval of Pompe disease therapy Amicus: Holding Until AT-GAA U.S. Approval Amicus Therapeutics: U.K. Approval Expands Global Reach Amicus closes up 5% as it expects app...

Pombiliti™ (cipaglucosidase alfa-atga) + Opfolda™ (miglustat) Approved in ERT-Experienced Adults First and Only Two-Component Therapy for Eligible Adults Living with Late-onset Pompe Disease Amicus Therapeutics to Host Conference Call Today ...

2023-09-27 16:35:27 ET More on Amicus Therapeutics Amicus: Holding Until AT-GAA U.S. Approval Amicus Therapeutics: U.K. Approval Expands Global Reach Amicus announces U.K. approval and launch of Pompe disease therapy Amicus Therapeutics reports mixed Q2 earni...

2023-09-06 08:12:04 ET Summary Protalix BioTherapeutics reported Q2 2023 revenues of $35.08 million, a 300.72% YoY increase, beating Wall Street estimates. The US FDA approved PLX's Elfabrio for the treatment of Fabry disease in adults, expanding its commercialization target. ...

PHILADELPHIA, Sept. 01, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in upcoming presentations at the following investor conferences in September. Morgan Stanley 21 st Annual Global Healthcare Conference in New York, NY o...

PHILADELPHIA, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced that one oral presentation and five posters across its development programs will be included at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium 2023 , bein...

2023-08-21 07:21:56 ET Biotechnology company Amicus Therapeutics ( NASDAQ: FOLD ) said on Monday that Simon Harford has been appointed CFO, effective immediately. Harford most recently served as a CFO at the Boston-based biotech Albireo Pharma, a pediatric liver...

Daphne Quimi to Retire At Year End PHILADELPHIA, Aug. 21, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for rare diseases, today announced that Simon Harford has b...